Phase 1 Ovarian Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You are 21 years of age or older
• You have been diagnosed with early-stage breast cancer (stage 1 or 2) that is considered low risk, finished your main treatments (surgery, chemotherapy, and/or radiation) more than 6 months ago, and your oncologist estimates your chance of the cancer coming back within 10 years is less than 20%
• OR you have been diagnosed with late-stage ovarian cancer (stage 3 or 4) that is considered high risk, you are currently in remission, and your oncologist estimates your chance of the cancer coming back within 10 years is more than 80%
• You are generally well enough to carry out light activity and daily self-care (confirm with trial site for specific fitness standards)
• You are able to swallow and take medication by mouth
• You are experiencing fear of your cancer coming back, both at the screening appointment and at the start of the study
• You have someone in your life who can accompany you home (or to another safe place) after each study dose
• If you are able to become pregnant, you agree to use reliable birth control throughout the study

Who may not be able to join:

• You have unstable or serious health conditions such as heart failure, certain heart rhythm problems, a recent heart attack, severely high blood pressure, kidney failure, severe liver problems, or breathing failure (confirm with trial site for full list)
• Your blood pressure at screening or at the start of the study is higher than 140/90 mmHg
• You have a significant brain or nervous system condition, such as epilepsy, a history of stroke, a brain tumour, a brain aneurysm, or dementia
• You have, or have had in the past, a serious mental health condition such as schizophrenia, schizoaffective disorder, bipolar disorder, or depression with psychotic features
• A close biological relative (such as a parent or sibling) has been diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features
• The study team believes, based on their clinical judgement, that you may be at risk of an unsafe emotional or behavioural reaction, such as severe agitation or violent behaviour
• You have had a moderate or severe alcohol or drug use problem within the past year (excluding caffeine and nicotine)
• You have used hallucinogenic substances such as LSD or psilocybin (magic mushrooms) in the last 12 months, or more than 25 times in your lifetime
• You have had significant thoughts of suicide or self-harm recently, as assessed using a standard clinical questionnaire (confirm with trial site for specific details)
• You have a history of a condition called hallucinogen persisting perception disorder (HPPD), where visual disturbances continue long after using a hallucinogenic substance
• You are currently pregnant or breastfeeding
• You show signs of significant memory or thinking difficulties, as measured by a standard cognitive test (confirm with trial site for specific score threshold)
• You are currently taking certain medications, including antidepressants, antipsychotics, mood stabilisers, certain herbal supplements (such as St. John's Wort), or several other specific drugs (confirm with trial site for the full list)
• You test positive for certain drugs in a urine test at the time of screening (unless the medication has been prescribed to you)
• The study team judges that a mental health condition would make it unsafe or unsuitable for you to participate
• The study team identifies any other physical symptom, medication, or finding that makes you unsuitable for the study, based on their clinical judgement
• You have a known allergy or intolerance to any ingredient in the study drug
• You do not speak English
• You are currently enrolled in another clinical trial focused on treating anxiety, depression, or emotional distress

Important: Always verify eligibility with the trial site directly before applying.